Abstract:
This study was conducted in response to recurring reports from Eastern Sudanof camel trypanosomosis that can no longer be treated by currently available trypanocidal drugs. We tried to assess the susceptibility ofTrypanosoma evansi isolated in Kassala State, eastern Sudan in December 2016. Two groups of Wistar albinorats (five rats/ group) experimentally infected with T. evansi were treated at day four post infection with either quinapyraminesulphateor diminazenediaceturate subcutaneously. A group of rats was left infected-non-treated while another group was left non-infected-non-treated. All groups were monitored daily for parasitemia using wet blood films up to day 18. We found that diminazenediaceturate has successfully treated the infected rats and completely cleared the parasitemia. In contrast, quinapyraminesulphate failed to cure the infected rats.
PCV at day 18 was also assessed to evaluate the level of anemia in all groups. The group treated with diminazenediaceturate showed normal PCV comparable to that of non-infected group confirming the complete recovery of rats. While the group treated withquinapyramineSulphate showed significantly lower PCV comparable to the infected-non-treated group.
It is concluded that the failure of treatment of infected rats withquinapyraminesulphatethis might represent an alert to the veterinary authorities in the country reflects that camels treated with the drug may not cure. Further studies are urgently needed to investigate whether the failure of treatment is due to the emergence of possible drug resistance
